Details

Autor(en) / Beteiligte

• Molina-Vega, María
• Picón-César, María J.
• Gutiérrez-Repiso, Carolina
• Fernández-Valero, Andrea
• Lima-Rubio, Fuensanta
• González-Romero, Stella
• Moreno-Indias, Isabel
• Tinahones, Francisco J.

Titel

Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial

Ist Teil von

• Biomedicine & pharmacotherapy, 2022-01, Vol.145, p.112465-112465, Article 112465

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Metformin, which is known to produce profound changes in gut microbiota, is being increasingly used in gestational diabetes mellitus (GDM). The aim of this study was to elucidate the differences in gut microbiota composition and function in women with GDM treated with metformin compared to those treated with insulin. From May to December 2018, 58 women with GDM were randomized to receive insulin (INS; n = 28) or metformin (MET; n = 30) at the University Hospital Virgen de la Victoria, Málaga, Spain. Basal visits, with at least 1 follow-up visit and prepartum visit, were performed. At the basal and prepartum visits, blood and stool samples were collected. The gut microbiota profile was determined through 16S rRNA analysis. Compared to INS, women on MET presented a lower mean postprandial glycemia and a lower increase in weight and body mass index (BMI). Firmicutes and Peptostreptococcaceae abundance declined, while Proteobacteria and Enterobacteriaceae abundance increased in the MET group. We found inverse correlations between changes in the abundance of Proteobacteria and mean postprandial glycemia (p = 0.023), as well as between Enterobacteriaceae and a rise in BMI and weight gain (p = 0.031 and p = 0.036, respectively). Regarding the metabolic profile of gut microbiota, predicted metabolic pathways related to propionate degradation and ubiquinol biosynthesis predominated in the MET group. Metformin in GDM affects the composition and metabolic profile of gut microbiota. These changes could mediate, at least in part, its clinical effects. Studies designed to assess how these changes influence metabolic control during and after pregnancy are necessary. [Display omitted] •In GDM, metformin increases Proteobacteria and Enterobacteriaceae abundance.•In GDM, metformin decreases Firmicutes and Peptoestreptococcaceae abundance.•Enterobacteriaceae increase was inversely correlated with BMI and weight gain.•Proteobacteria increase was inversely correlated with mean postprandial glycemia.